ADVERTISEMENT
ADVERTISEMENT

Philanthropic Funding Provided by:

Tx name MPP-021
Description A clinically validated cognitive enhancer with newly discovered anticonvulsant, neuroprotective and analgesic effects is in development as the multifunctional mechanism-based CNS drug candidate for the treatment of neurological and neurodegenerative diseases and disorders. Novel analogs of MPP-021 have improved profile as potential AEDs and adjuvant analgesics, particularly for the treatment of neuropathic pain.
Company MediProPharma
Status  
Overview Challenges: Selection of at least two therapeutic indications for clinical development of MPP-021 to maximize the drug developmental potential. Identification of the IND candidate as a novel AED and adjuvant analgesic from novel analogs of MPP-021 via comprehensive in vivo profiling of at least two candidate compounds.
PK  
indications  
preclin data  
preclin tox  
Phase 1  
Phase 2  
Phase 3  
Adverse effects  
publications  
IP  
Potential problems  
Timeline  
Financial Status  
Partnerships Need Early-stage partnering with big pharma or Series B investment in mid-2010.
ETP Support  
ADVERTISEMENT
ADVERTISEMENT